Your Trusted Guide to Psilocybin
& Magic Mushrooms
Evidence-based guides, harm-reduction tools, and a verified directory of psychedelic churches — all free.
Start here
Essential guides
Psilocybin Therapy
The three-phase protocol, what the trials show, and how legal access works in Oregon and Colorado.
Read guide →Safe Trip Guide
Set, setting, preparation, navigating hard moments, and the integration period that follows.
Read guide →Microdosing Guide
Schedules, dose ranges, and what published studies do (and do not) support for microdosing.
Read guide →MAPS Files Comments in FDA's Psychedelic Therapy Docket. Here Is What That Docket Can Actually Do.
MAPS announced on 20 October 2026 that it and founder Rick Doblin submitted written comments to FDA on psychedelic-assisted therapy standards. The post is password-protected, so nobody outside MAPS can read what was filed. The docket its...
Read the full breakdown →Dosage calculator, calibrated to published studies.
Body-weight adjusted ranges for dried P. cubensis, drawn from Johns Hopkins and Imperial College protocols. Start low. Potency varies ±30% between specimens — always titrate, never stack.
Educational estimate only. Not medical advice. Always start lower than calculated, and know your source.
Evidence by condition
Psilocybin for mental health
Depression
Treatment-resistant and major depression. The COMP360 program and what comes next for real-world access.
Alcohol Use Disorder
Reductions in heavy-drinking days reported in published trials, and how the facilitated protocol is structured.
End-of-Life Anxiety
Palliative settings showing rapid, durable reductions in existential distress under well-characterized protocols.
PTSD
How psilocybin research is positioned alongside other trauma therapies, and the open questions that remain.
OCD
Small studies suggesting reduced intrusive thoughts. Trials are underway but not yet powered for efficacy claims.
Cluster Headaches
Observational reports of "breaking the cycle." Dose-response is not yet characterized in a controlled setting.
Directory
Common psilocybin-active species
Psilocybe cubensis
Well-StudiedBehind most cultivars and the vast majority of clinical trials. Effects are better documented than for rarer species.
Psilocybe semilanceata
Some DataSmall and potent, common in temperate pasture. Less trial data than cubensis but extensively used historically.
Psilocybe azurescens
Limited DataVery potent; Pacific Northwest native. Treat potency and set/setting with extra care — easy to overshoot.
Psilocybe cyanescens
Some DataPNW and European. Fruits on wood chips in cool months. Potency variable between patches; start lower than expected.
Psilocybe mexicana
Well-StudiedHistorical Mesoamerican ceremonial species. Milder than cubensis, extensively studied in ethnobotany literature.
Psilocybe baeocystis
Limited DataPNW native. Limited modern data; potency reports inconsistent. Identification is tricky for beginners.
From the desk of PsyBear Editorial
Latest research & analysis
Brazil Is Reopening Its Ayahuasca Rules. Psilocybin Is Not in the Room.
Chacruna's "Psychedelic Dawn at the Edge of the Global South" lands four days before Brazil's presidential runoff. The live regulatory story is narrower and more concrete than t...
Psilocybin Is America's Most-Used Psychedelic. The Evidence Hasn't Caught Up.
DoubleBlind is right about the direction: three separate national surveys released in 2026 all put psilocybin at the top. What they measure, though, is unsup...
MAPS Launches a Practitioner Alliance. Who Actually Gets to Credential a Psilocybin Guide?
On October 5, 2026, MAPS announced a partnership with the International Alliance of Psychedelic Therapy Practitioners to build "clinical and ethical standard...
Get the weekly research digest.
Join free for our weekly research digest, plus community updates and harm-reduction news. One email a week — no spam.